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Abstract
Objective: To identify a new genetic cause in patients segregating distal hereditary motor neuropathy (dHMN) with an autosomal recessive pattern. Methods:
Whole-exome sequencing was conducted in two siblings and was combined
with segregation analysis. Additionally, 83 unrelated dHMN patients with
unknown genetic cause were screened. RNA analysis was performed using blood
lymphocytes and HEK293 cells transfected with mutant plasmids. Immunohistochemistry and Western blot analysis was applied to the nerve tissue. The
enzymatic activities of mutant proteins were measured in the cultured cells to
verify the pathogenicity of variants. Results: The clinical features of the patients
showed late-onset phenotype of distal motor neuropathy without sensory
involvement. We identified that compound heterozygous variants of c.1342C>T
and c.2071_2072delGCinsTT in the membrane metalloendopeptidase (MME)
gene co-segregated with the phenotype in a dHMN family. In an additional
group of 83 patients with dHMN, compound heterozygous variants of
c.1416+2T>C and c.2027C>T in MME were identified in one patient. The splice
site variant c.1416+2T>C results in skipping of exon 13. The stop variant
c.1342C>T induces mRNA degradation via nonsense-mediated mRNA decay.
Transcript levels of MME in the lymphocytes showed no significant differences
between the patients and controls. We also identified that MME variants were
associated with mild decrease in protein expression in the sural nerve and significant impairments of enzymatic activity. Interpretation: Variants in the
MME gene were associated with not only a Charcot-Marie-Tooth neuropathy
phenotype but also with an autosomal-recessive dHMN phenotype. Loss of
function may play a role in the pathogenesis of dHMN.

Introduction
Distal hereditary motor neuropathy (dHMN), also known
as distal spinal muscular atrophy (SMA), is a group of
pure motor neuropathies characterized by progressive
1728

distal muscle weakness and atrophy without clinical or
electrophysiological sensory abnormalities.1 At least 30
genes or loci have been associated with dHMNs with
autosomal dominant, autosomal recessive, or X-linked
inheritance.2 Autosomal recessive dHMNs have been
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associated with mutations in the IGHMBP2, PLEKHG5,
DANJB2, SIGMAR1, SYT2, HSPB1, ATM, TBCE, and
VRK1 genes.3 However, the underlying genetic variants
have yet been discovered in more than one-half of
patients with dHMN.4
Membrane metalloendopeptidase (MME), also referred
to as neprilysin or neutral endopeptidase (NEP), is a neutral transmembrane endopeptidase that hydrolyses peptides at the amino side of hydrophobic residues and
inactivates several peptide hormones.5 MME is expressed
in a variety of normal tissues, especially is enriched in the
peripheral nerves.6 The heterozygous mutations in MME
have been associated with late-onset axonal CharcotMarie-Tooth neuropathy (CMT2), 7 unspecified polyneuropathy, amyotrophic lateral sclerosis, sensory ataxia,
cluster headache,8 and dominant spinocerebellar ataxia
with neuropathy (SCA43),9 whereas homozygous or compound heterozygous mutations in MME cause autosomal
recessive CMT2.10 Several forms of dHMNs exhibit phenotypic overlaps with CMT2 that is a motor-predominant
inherited neuropathy with subclinical sensory involvement.11–14 However, no patients with dHMN phenotype
caused by MME variants have been reported to date. In
this study, we identified that compound heterozygous
variants in the MME gene were associated with dHMN in
two siblings, and further investigated the MME variants
in 83 unrelated patients with dHMN of unknown genetic
causes.

Subjects and Methods
Subjects
A nonconsanguineous family A with two affected siblings
was initially recruited in this study (Fig. 1A). Clinical
evaluations were conducted in 15 members (I:1, I:2, II:1,
II:2, II:3, II:4, II:5, II:6, II:7, II:8, III:1, III:2, III:3, III:4,
and III:5) from this family by two experienced neurologists. The age at onset, progression of disability, and clinical manifestations were collected. The standard
electrophysiological examinations were performed on the
affected patients. Brain and spine MRI were also taken on
the affected patients. All individuals involved in the study
signed written informed consent before they were enrolled
in the study. This study was approved by the ethics committees of the Peking University People’s Hospital and
the First Affiliated Hospital of Nanchang University.

Exome sequencing
Targeted exon enrichment was performed using SureSelect Human All Exon V5 (Agilent Technologies, Santa
Clara, CA). The exon-enriched DNA libraries were

subjected to paired-end sequencing on a Hiseq2000 platform (Illumina, Inc., San Diego, CA). Sequence data were
mapped with BWA and SAMTOOLS onto the hg38
human genome as a reference. Calls with variant quality
less than 20 were filtered out and 95% of the targeted
bases were covered sufficiently to pass our thresholds for
calling single-nucleotide polymorphisms (SNP) and small
insertions or deletions (indels; Otogenetics Corporation,
Norcross, GA). In order to confirm the variants, fragments containing the MME variants were amplified for
direct Sanger sequencing in the patient II:2 and all family
members available.

Additional patients screening
To validate whether MME variants are associated with
dHMN, genetic testing was performed on an additional
83 dHMN patients with unknown genetic cause using targeted next-generation sequencing panel for inherited neuromuscular disorders that included the MME gene. These
patients were recruited from 10 medical centers between
January 2014 and December 2018. The clinical information was listed in Table S1.

RNA transcript study
RNA was extracted using the RNeasy Mini Kit (Qiagen,
Duesseldorf, Germany) according to the manufacturer’s
instructions from the blood lymphocytes of three patients,
two carrier subjects (I:1 of family A and I:1 of family B),
and a normal control participant. The extracted RNA was
converted to cDNA using the SuperScript First-Strand
Synthesis System (Life Technologies, Carlsbad, CA) with
random hexamer primers. The RNA concentration was
measured using a NanoDrop1000 (Thermo Scientific,
Waltham, MA). To evaluate the transcript result of the
c.1416+2T>C variant, a fragment between the exon 11
and exon 15 of the cDNA of MME (ENST00000460393.5)
was amplified by polymerase chain reaction (PCR) using
primers of MME-11F (50 -TGGATCTTGTAAGCAG
CCTCA-30 ) and MME-15R (50 -TCCACCTTTTCTCGGAGCTT-30 ). The PCR products were analyzed by agarose gel electrophoresis and Sanger sequencing.
The mammalian pCAG-T7pol plasmids with CMV
enhancer/chicken beta actin promoter (gift from Dr.
Zhongming Liu) harboring wild-type MME or mutant
MME (c.1342C>T) were transfected into HEK293 cells for
their overexpression. To explore the presence of nonsense-mediated mRNA decay, cells were split into two
subcultures. One subculture remained untreated, whereas
the other one was exposed to 150 mg/mL cycloheximide
(Sigma-Aldrich, Santa Clara, CA) at 37°C for 4 h. After
incubation, the cells were washed with Dulbecco’s
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Figure 1. Family pedigrees and illustrations of distal limbs. (A) Family pedigree A shows two patients (arrow indicates the index patient II:2; black
square indicates the other patient II:5). The genotype segregates with the phenotype in the family (+ indicates mutant allele;  indicates wild-type
allele). (B) Family pedigree B shows an additional patient II:2 (black circle). Genetic screening reveals a family co-segregation (+ indicates mutant
allele;  indicates wild-type allele). (C) The patient II:2 of family A shows mild intrinsic muscle atrophy of feet and hands. (D) The patient II:5 of
family A has wasting of the lower limbs and left hand. (E) The patient II:2 of family B displays wasting of distal lower limbs and pes cavus.

phosphate-buffered saline (Thermo Scientific) and subsequently harvested by centrifugation.
Quantitative PCR (qPCR) was utilized for relative
quantification of MME transcripts level. cDNA (10 ng)
from each sample was amplified using a Fast SYBR Green
master mix (Life Technologies) with primers for MME (F:
50 -TGATCGCACTCTATGCAACC-30 ; R: 50 -GCTCCCA
GTTTTCTGTTGCT-30 ) and beta-actin (F: 50 -CCTCGCC
TTTGCCGATCC-30 ; R: 50 -GGATCTTCATGAGGTAGTCAGTC-30 ). The qPCR data were analyzed by the
ViiATM7 PCR system (Life Technologies). Measurements
were normalized against the beta-actin gene. Levels of
mutant transcript from the patients were quantified relative to the level of wild-type transcript from a control. An
unpaired t-testing was used to compare the normalized
and relative mean DCt values between the patients and
control subjects. Statistical analyses were performed using
SPSS software.

MME expression and activity measurement
Sural nerve biopsy was performed on the patient II:2 of
family A. Semithin sections of the specimen for light
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microscopy were stained with toluidine blue. The expression of MME protein in sural nerves was detected by
immunohistochemical stain using mouse monoclonal
MME antibody (UM870128, OriGene Technologies, Rockville, MD).
The sural nerve biopsy samples were homogenized, separated on a SDS-PAGE gel, and then transferred to nitrocellulose membrane. The Nitrocellulose strips were
probed with antibody against MME (UM870128, OriGene
Technologies). The membrane was subsequently incubated with horseradish peroxidase-conjugated secondary
antibody (Chemicon, Temecula, CA). Chemiluminescent
signals were digitally imaged (ECL-Plus, Amersham, Little
Chalfont, Buckinghamshire, UK).
The cDNA encoding human wild-type MME was
amplified by PCR and subcloned into pCAG-T7pol plasmid through the Kpnl and Xbal endonuclease. The plasmids expressing the mutants c.1342C>T, c.1884C>G,
c.2027C>T, and c.2071_2072delGCinsTT were generated
by site-directed mutagenesis according to the manufacturer’s procedure (Takara MutantBEST Kit, Tokyo,
Japan). HEK293 cells were cultured in DMEM with 10%
v/v fetal bovine serum. Cells were transfected using
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Lipofectamine 2000 (Invitrogen, Carlsbad, CA) according
to the manufacturer’s procedure. After 24 h, cells were
incubated with 100 lL reaction mixture containing
10 lmol/L of the MME substrate fluorescent Mca-PLGLDpa-AR-NH2 (R&D Systems, Minneapolis, MN). Fluorescence signal intensity of the cell supernatant was measured using a PekinElmer FL 8500 reader (Waltham, MA)
with excitation at 320 nm and emission at 405 nm.
Quantitative experiments were performed in triplicate
and results were presented as mean  standard deviation.
For statistical analysis, one-way ANOVA with Bonferroni
post hoc test was used.

Result
Clinical features
The index patient was a 54-year-old woman from a nonconsanguineous family A (Fig. 1A II:2). She initially had
muscle weakness of lower limbs at the age of 50. She complained of slow walking, muscle soreness, and falling down
due to an uneven ground. Subsequently, she started having muscle weakness and tremors in both hands. Physical
examination revealed mild atrophy of the intrinsic muscles
of her feet and hands (Fig. 1C). Arthrogryposis or joint
contracture was not detected in the lower limbs, but interphalangeal joint contracture of the left hand little finger
was noted. Her muscle strength grade was 5/5 (Medical
Research Council Scale) in the proximal limbs, 3/5 in the
extensor digitorum brevis, 3/5 in the foot dorsiflexion,
and 4/5 in the foot plantarflexion, respectively. Deep tendon reflexes were diminished in both lower limbs. Pain,
light touch, vibration, and joint position sensations were
normal. Babinski sign was negative on both sides. The
clinical manifestations were summarized in Table 1.
The younger brother of index patient was 50 years of
age (Fig. 1A II:5). He first reported mild motor disability
of the lower limbs at the age of 45, and hand weakness at
the age of 49. Physical examination revealed distal motor
weakness, wasting in the lower limbs and left hand, and
pes cavus (Fig. 1D). Deep tendon reflexes were absent in
the lower limbs. Pain, light touch, vibration, and joint
position sensations were intact. There was no evidence of
ataxia, tremor, or pyramidal tract signs. Other family individuals available were normal in the clinical evaluation.
The third patient was a 24-year-old woman from a
nonconsanguineous family B (Fig. 1B II:2). She was identified in a group of 83 dHMN patients with unknown
genetic cause. She had experienced a slowly progressive
gait disturbance of the lower limbs since 16 years old. She
presented with insidious wasting and weakness of distal
lower limbs involving the foot dorsiflexors more severe
than the plantar flexors, and developed foot drop and pes

Table 1. Clinical features of the patients with MME-related dHMN.
Variable

Family A II:2

Family A II:5

Family B II:2

Sex
Age at onset (year)
Age at examination
(year)
Symptoms at onset

female
50
54

male
45
50

female
16
24

Weakness of
LL

Weakness of
LL

Weakness of
LL

Mild
moderate

mild
moderate

moderate
severe

+
++
+
+

+
++



++
+++
+
+



+


30/30

+




29/30

+




30/30

Muscle wasting
Upper limbs
Lower limbs
Muscle weakness1
Upper limbs
Lower limbs
Postural tremor
Finger joint
contraction
Pes cavus
Babinski reflexes
Knee reflexes
Ankle reflexes
Sensory symptoms
MMSE score

MME, membrane metalloendopeptidase; dHMN, distal hereditary motor
neuropathy; LL, lower limb; MMSE, Mini-mental State Examination.
1
Patients with distal muscle weakness, : normal; +: <4 grade in distal muscles; ++: ≥2 grade in distal muscles; +++: <2 grade in distal
muscles.

cavus (Fig. 1E). Progressive wasting of hand intrinsic
muscles and disability to straighten her fingers became
obvious at 22 years of age. Deep tendon reflexes were
absent in the lower limbs. Pain, light touch, vibration,
and joint position sensations were intact. There was no
evidence of ataxia, tremor, or pyramidal tract signs.

Electrophysiological study
The motor nerve conduction velocities were moderately
reduced, but the amplitudes of compound muscle action
potentials severely decreased. Furthermore, the motor
nerves of lower limbs were more severely affected than
those of upper limbs. The sensory nerve conduction
velocities and action potentials were not affected in all
three patients. Detailed nerve electrophysiological data are
listed in the Table 2. For all three patients, needle electromyogram revealed distal denervation featured by the
increased amplitude and duration of motor unit action
potential during slight contraction, and reduced recruitment on voluntary contraction recorded in distal limbs.

Genetic findings
In the exome-sequencing process, after quality control
and coverage criteria were met, we started with a total of
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50,162 SNP and 2623 indels. Since hereditary motor neuropathy is a rare disorder but has a clear phenotype, there
was a low likelihood that a causal mutation in the patient
II:2 of family A was present in control populations. We
therefore filtered for novel variants by comparing our
exome data to several databases including dbSNP build
132, the 1000 Genomes Project, ExAC database, GnomAD, Hapmap, YH project, and the National Heart,

Lung, and Blood Institute Exome Sequencing Project.
After the exome capture sequencing and variant analysis,
318 variants under the dominant mode (220 SNP and 98
indels) and 52 variants under the recessive mode (41 SNP
and 11 indels) were identified.
Comparing the candidate genes with the reported genes
related to inherited peripheral neuropathies, we discovered that MME was on the candidate gene list with

Table 2. Electrophysiological studies in patients with MME-related dHMN.
Family A II:2
Motor nerve
L Median
E-W
W-APB
R Median
E-W
W-APB
L Ulnar
E-W
W-ADM
R Ulnar
E-W
W-ADM
L Peroneal
FH-A
A-EBD
R Peroneal
FH-A
A-EBD
L Tibial
PF-A
A-AA
R Tibial
PF-A
A-AA
Sensory nerve
L-Median
IIIF-W
R-Median
IIIF-W
L Ulnar
VF-W
R Ulnar
VF-W
L-Sural
A-SURA
R-Sural
A-SURA

MNCV (m/sec)

Family A II:5

dL (msec)

CMAP (mV)

MNCV (m/sec)

10.1
9.8

46.0

3.3

7.5
6.7

50.0

3.8

6.5
7.0

43.0

2.4

5.0
4.3

51.2

2.7

1.1
0.8

39.0

4.4

0.8
1.0

38.8

4.7

0.4
0.2

29.0

4.5

0.1
0.0

38.0

4.7

50.0

52.6

51.5

56.0

40.8

41.2

33.3

29.4

Family B II:2

dL (msec)

CMAP (mV)

MNCV (m/sec)

4.2
5.1

48.6

3.5

7.2
8.9

50.0

3.7

10.3
12.1

42.0

2.0

10.1
11.2

41.0

2.7

0.5
0.5

37.5

4.5

0.8
0.7

35.0

4.8

0.2
0.1

28.5

5.0

0.2
0.3

30.3

4.6

dL (msec)

CMAP (mV)

3.4

4.9
6.7

3.8

8.2
8.9

2.4

4.3
4.1

2.6

2.5
3.2

5.5

0.3
0.6

4.8

0.7
0.9

5.1

0.3
0.0

4.6

0.2
0.1

SNCV (m/sec)

dL (msec)

SNAP (lV)

SNCV (m/sec)

dL (msec)

SNAP (lV)

SNCV (m/sec)

dL (msec)

SNAP (lV)

60.8

2.3

76.7

56.7

2.6

72.8

58.8

2.5

67.5

55.7

2.6

83.2

60.7

2.4

80.1

51.5

3.0

75.3

50.4

2.3

63.2

48.6

2.3

66.8

47.3

2.6

72.8

39.2

2.3

83.5

49.5

2.3

78.3

41.6

2.7

73.1

50.0

2.9

8.5

51.0

2.8

8.8

43.7

3.5

8.1

46.9

3.3

9.2

48.3

3.0

8.9

49.3

2.8

8.6

MME, membrane metalloendopeptidase; dHMN, distal hereditary motor neuropathy; MNCV, motor nerve conduction velocity; CMAP, compound
motor action potential; dL, distal motor latency; SNCV, sensory nerve conduction velocity; SNAP, sensory nerve action potential; E, elbow; W,
wrist; APB, abductor pollicis brevis; ADM, abductor digiti minimi; PF, popliteal fossa; A, ankle; FH, fibula head; EDB, extensor digitorum brevis;
AA, abductor allucis; IIIF, third finger; VF, fifth finger. SURA, sural; Normal values are given in brackets.
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compound heterozygous variants of c.1342C>T (p.R448*)
and c.2071_2072delGCinsTT (p.A691L). Sanger sequencing confirmed the heterozygous variants in the patient
II:2 (Fig. 2A) and patient II:5 of family A. The variant of
c.1342C>T was from the father, and the variant of
c.2071_2072delGCinsTT was from the mother. The
genetic screening in the family further demonstrated that
the genotype co-segregated with the phenotype (Fig. 1A).
In an additional case series of 83 patients with dHMN,
one patient (patient II:2 of family B) with compound
heterozygous variants of c.1416+2T>C (p.V440_K472del)
and c.2027C>T (p.P676L) in the MME gene were identified (Fig. 2B). Sanger sequence revealed that the variant
of c.1416+2T>C was from the father, and the variant of
c.2027C>T was from the mother, indicating a family cosegregation (Fig. 1B).
The novel variants c.1416+2T>C, c.2027C>T, and
c.2071_2072delGCinsTT have not been found in the 1000
genomes database, ExAC database, or gnomAD database,
whereas the variant of c.1342C>T has been reported in
patients with CMT.7 A homology search in different species demonstrated that the amino acids at the residues
proline 676 and alanine 691 were highly evolutionarily
conserved (Fig. 2C). The missense variants of p.P676L

MME Associated With AR-dHMN

and p.A691L were predicted to be probably destructive
with PolyPhen-2 scores of 1.00, deleterious with a SIFT
score of 0.00, and disease causing by MutationTaster,
respectively. The donor site variant c.1416+2T>C changed
the splice score from 0.91 to 0 predicted by NetGene2
server. The variants were considered as pathogenic
according to the American College Medical Genetics
guidelines.15 No other causative mutations associated with
inherited peripheral neuropathies were found in the three
patients.

RNA expression analysis
To evaluate the outcome of the novel donor site variant,
RNA analysis was conducted on the patient II:2 of family
B. The sequences of RT-PCR products revealed aberrantly
spliced mRNA lacking exon 13, resulting in a loss of 99bp fragment (Fig. 3A). The skip of exon 13 leads to an
in-frame deletion of 33 amino acids (p.V440_K472del)
from the extracellular catalytic domain of MME (Fig. 3B).
Premature stop variants might induce mRNA degradation
via nonsense-mediated mRNA decay. The mRNA level of
MME in the lymphocytes mildly decreased in the three
patients compared to a control, but no significant

Figure 2. The genetic variants in the MME gene. (A) Electrophoregrams show that the patient II:2 of family A has compound heterozygous
variants (variants at upper; wild-type at below). (B) Electrophoregrams show that the patient II:2 of family B has compound heterozygous variants
(variants at upper, wild-type at below). (C) Residues proline 676 and alanine 691 have high evolutionary conservations. (D) Schematic
representation of the MME gene and distribution of mutations reported. The mutations in MME are associated with dominant CMT2 (black font),
recessive CMT2 (red font), dominant SCA43 (green font), and recessive dHMN (blue font). MME, membrane metalloendopeptidase; CMT2,
Charcot-Marie-Tooth neuropathy; SCA43, spinocerebellar ataxia with neuropathy.

ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

1733

MME Associated With AR-dHMN

difference was identified between each other (Fig. 3C).
However, the HEK293 cells transfected with c.1342C>T
mutant contained only about 10% MME mRNA compared to that of wild-type cells (Fig. 3D). Transcript levels
could be increased after treatment with the translation
inhibitor cycloheximide which blocks nonsense-mediated
mRNA decay.

D. Hong et al.

showed a normal 100kDa band and a truncated 75kDa
band in the homogenates from the sural nerve (Fig. 4E),
indicating a small amount of truncated protein still being
produced, though a premature stop variant induced
mRNA degradation through nonsense-mediated mRNA
decay.

MME enzymatic activity
Histopathological findings and expression
of neprilysin
A biopsy of the sural nerve was obtained from patient II2
of family A. Semithin sections showed relatively normal
density and structure of large myelinated fibers, except
very few fibers with thin myelin sheaths (Fig. 4A and 4).
No axonal degeneration, clusters of myelinated fibers, or
onion-bulb formation were found. Immunohistochemical
stain with an anti-MME antibody showed a mild decrease
in positive reaction to nerve fibers (Fig. 4C) compared to
the sural nerve from the control (Fig. 4D). Immunoblot

MME enzymatic activity was determined in HEK293 cells
transiently transfected with plasmids encoding wild-type
human MME, disease mutants (c.1342C>T, c.2027C>T,
and c.2071_2072delGCinsTT), and a proven mutant
c.1754A>T (p.E585V) that results in the loss of NEP
activity. As expected, the artificial control mutant almost
abolished catalytic activity toward the substrate McaPLGL-Dpa-AR-NH2 compared with the background level
of the empty vector control. The disease-associated MME
mutants showed significant decreases in MME enzymatic
activity (Fig. 4F).

Figure 3. Genetic mutation analysis and RNA expression measurement. (A) Gel electrophoresis shows a loss 99-bp fragment in the patient II:2
and her father (I:1) of the family B. (B) Electrophoregram of the RT-PCR products reveals skipping of exon 13 in the MME transcript with
c.1416+2T>C mutation. (C) Quantitative PCR showing mRNA levels of MME from patient and carrier lymphocytes relative to a control. Bars show
the mean mRNA levels  standard deviation relative to the control which has been set to +1. (D) HEK293 cells transfected with c.1342C>T
mutant contain only about 10% MME mRNA compared to that of wild-type cells, but the transcript of mutant MME is recovered after
administration of cycloheximide (*P < 0.001). Bars show the mean mRNA levels  standard deviation relative to the wild-type which has been set
to +1. MME, membrane metalloendopeptidase; PCR, polymerase chain reaction.
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Figure 4. Histopathological findings and expression of MME. (A) Semithin section of sural nerve from the patient II:2 of family A shows a
relatively normal density and structure of nerve fibers. (B) The magnification of square in the fig. A reveals few fibers with thin myelin sheaths
(arrows). Mild decrease in positive reaction to the nerve fibers in the patient (C) compared to a control (D) by anti-MME monoclonal antibody. (E)
Immunoblot reveals a normal band and a truncated band in the homogenates of sural nerve with c.1342C>T premature mutant. (F) The diseaseassociated MME mutants have significant decreases of MME enzymatic activity compared to the wild-type (*P < 0.05, **P < 0.001). Bars show
the mean levels  standard deviation relative to the empty vector which has been set to +1. MME, membrane metalloendopeptidase.

Discussion
Distal HMNs are a group of clinically and genetically
heterogeneous disorders caused by the dysfunctions of

motor neurons in the peripheral nervous system (PNS).
The phenotype of dHMN typically presents with a lengthdependent motor weakness and wasting, initially affecting
the intrinsic foot muscles and the peroneal compartment
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of the leg, but most cases show variable involvement of
the hand and proximal leg muscles as the disease progresses.16 In this study, the affected siblings presented
with late-onset muscle weakness and wasting of lower
extremities, whereas the additional patient showed a juvenile-onset phenotype of moderate muscle weakness and
wasting involving both the upper and lower limbs.
Although all patients presented with some extents of clinical heterogeneity, the clinical features were confined to
pure axonal-type motor neuropathy without sensory
abnormalities. Therefore, these patients could be diagnosed as dHMN based on the clinical and electrophysiological evidence.
Family studies indicated that MME variants co-segregated the phenotype in consistent with an autosomal-recessive inheritance. Autosomal-recessive dHMN is
relatively rare and often clinically more severe.17 Patients
with recessive dHMNs usually present with child-onset
distal extremity weakness and decrementation of life
expency.18,19 Our patients showed a late-onset phenotype
of distal motor symptoms, athough the juvenile-onset
patient had a moderate phenotype, which suggests that
MME-related dHMN may have a relatively benign clinical
course.
The defects of MME have been identified in patients
with autosomal dominant or recessive CMT2.7,9,20 Autosomal-recessive variants of MME cause late-onset CMT2,
which displays as adult-onset progressive weakness and
atrophy of distal limb muscles, gait disturbance without
wheelchair dependence, and sensory disturbance of the
distal limbs.10 However, autosomal-dominant variants of
MME were linked to patients with late adult-onset muscle
weakness, muscle cramps, gait abnormalities with wheelchair dependence occasionally, and sensory disturbances.7,20 Patients with heterozygous variants (c.466delC
or c.674G>C) reported by Auer-Grumbach et al.7 or Lupo
et al.20 also showed muscle cramps in legs, fasciculation,
distal lower limb weakness, stepagge gait, and very mild
or negative distal sensory loss, suggesting that MME variants might be linked to a possibility of dHMN in those
patients.7 dHMN shows apparent phenotypic overlap with
CMT2, and also with proximal SMA, motor neuron diseases, hereditary spastic paraplegias, and other neurologic
abnormalities.12 At least 10 genes (AARS, BCSL2,
DHTKD1, DYNC1H1, GARS, HSPB1, HSPB8, IGHMBP2,
MFN2, and TRPV4) have phenotypic overlaps between
dHMN and CMT2.2 Therefore, it is possible that MME
variants may also contribute to the etiology of conditions
beyond CMT2, most plausibly dHMN. To the best of our
knowledge, our study, for the first time, reported that
recessive variants of the MME gene could be associated
with dHMN. However, the identification of pathogenic
mutations in the same gene associated with both dHMN
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and CMT2 indicates that these two diseases should belong
to a continuum of MME-related disorders.
MME is a zinc-dependent metalloprotease that comprises a short N-terminal cytoplasmic domain, a single
transmembrane helix, and a large C-terminal extracellular
portion composed of two major alpha-helical (peptidase
M13) domains connected by a linker region (Fig. 2D).21
The variants associated with recessive CMT2 cause loss of
MME expression.10 For example, the homozygous premature mutations of p.G179fs, p.G221*, p.C411del,
c.439+2T>A, c.655-2A>G, and compound heterozygous
mutations of c.439+2T>A and c.655-2A>G located in the
N-terminal peptidase M13 domain. The mutations of
p.T606* and p.C621R located in the C-terminal peptidase
M13 domain would cause loss of function through nonsense-mediated RNA decay or loss of a disulfide bridge
with N-terminal peptidase M13 domain, respectively. In
our dHMN patients, the heterozygous variants p.R448*
and p.V440_K472del are possibly associated with the loss
of its enzyme activity of both N-terminal and C-terminal
peptidase M13, but the variants p.P676L and p.A691L
may only be associated with the function loss of enzyme
activity of C-terminal peptidase M13. Therefore, the loss
of function in both N-terminal and C-terminal peptidase
M13 might be related to motor CMT2 phenotype.10
However, the loss of C-terminal peptidase M13 and partial preservation of N-terminal peptidase M13 might be
associated with dHMN phenotype.
MME has been found not only in the central nervous
system (CNS), but also the PNS in mammals.6 MME has
been well studied in the CNS for its b-amyloid (Ab)-degrading enzymatic activity, though elusive conclusions
remains about its pathogenicity to Alzheimer’s disease in
humans.22 Although we are not aware of a direct link
between MME and the maintenance of PNS, it is conceivable that MME, as a cleaving enzyme, might be responsible for the turn over molecules that are critical for the
well-being of peripheral nerves, or the degradation of
peptides that have negative effects on neurons and
peripheral nerves.23 The role of MME in PNS is unclear
and warrants further investigation. The expression of
MME in the sural nerve was significantly decreased in
patients with autosomal-recessive CMT2,10 while its
expression was only mildly decreased in our patient,
implying a subclinically biochemical alteration in sensory
nerve, even though the patient currently presented with a
dHMN phenotype. Therefore, a long-term follow-up is
warranted in order to determine whether sensory disturbances would involve in the lower limbs of patients with
autosomal-recessive MME variants as the disease progresses.24
Our study indicates that variants in the MME gene are
associated with autosomal-recessive dHMN. The affected
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patients with MME-related dHMN show a late-onset phenotype with a relatively benign course. The expanding
number of genes assigned to the “CMT2-dHMN spectrum” should include the MME gene according to our
observations.

Acknowledgments
The authors appreciate the patients and their families for
their enthusiasm and participation in this study. We
thank Professor Liu Zhongming from Tsinghua University
who provided the pCAG plasmid. This work was supported by the National Natural Science Foundation of
China (No. 81460199 and 81870996) and Peking University People’s Hospital Research and Development Funds
(RDX2018-08).

7.

8.

9.

10.

11.

Author Contributions
D. H. contributed to the study design, data acquisition,
analysis, and manuscript preparation. S. Y., P. F., J. C., X.
Z., S. C., J. Z., D. T., L. W., X. H., Y. W., and M. L. contributed to data acquisition and analysis. L. X. and J. Z.
gave critical suggestions on the manuscript writing. L. C.
contributed to genetic analysis. S. Z. contributed to
pathological analysis. H. O. contributed to experimental
analysis. X. G. interpreted the data; revised the manuscript for intellectual content.

12.

13.

14.

Conflict of Interest
The authors report no disclosures relevant to the manuscript.

15.

Reference
1. Garcia-Santibanez R, Burford M, Bucelli RC. Hereditary
motor neuropathies and amyotrophic lateral sclerosis: a
molecular and clinical update. Curr Neurol Neurosci Rep
2018;18:93.
2. Rossor AM, Evans MR, Reilly MM. A practical approach
to the genetic neuropathies. Pract Neurol 2015;15:187–
198.
3. Parman Y, Battaloglu E. Recessively transmitted
predominantly motor neuropathies. Handb Clin Neurol
2013;115:847–861.
4. Bansagi B, Griffin H, Whittaker RG, et al. Genetic
heterogeneity of motor neuropathies. Neurology
2017;88:1226–1234.
5. Turner AJ, Isaac RE, Coates D. The neprilysin (NEP)
family of zinc metalloendopeptidases: genomics and
function. BioEssays 2001;23:261–269.
6. Kioussi C, Matsas R. Endopeptidase-24.11, a cell-surface
peptidase of central nervous system neurons, is expressed

16.
17.

18.

19.

20.

by Schwann cells in the pig peripheral nervous system. J
Neurochem 1991;57:431–440.
Auer-Grumbach M, Toegel S, Schabh€
uttl M, et al. Rare
variants in MME, encoding metalloprotease neprilysin, are
linked to late-onset autosomal-dominant axonal
polyneuropathies. Am J Hum Genet 2016;99:607–623.
Bacchelli E, Cainazzo MM, Cameli C, et al. A genomewide analysis in cluster headache points to neprilysin and
PACAP receptor gene variants. J Headache Pain
2016;17:114.
Depondt C, Donatello S, Rai M, et al. MME mutation in
dominant spinocerebellar ataxia with neuropathy (SCA43).
Neurol Genet 2016;2:e94.
Higuchi Y, Hashiguchi A, Yuan J, et al. Mutations in
MME cause an autosomal-recessive Charcot-Marie-Tooth
disease type 2. Ann Neurol 2016;79:659–672.
Luigetti M, Fabrizi GM, Bisogni G, et al. Charcot-MarieTooth type 2 and distal hereditary motor neuropathy:
clinical, neurophysiological and genetic findings from a
single-centre experience. Clin Neurol Neurosurg
2016;144:67–71.
Scarlato M, Vigan
o F, Carrera P, et al. A novel heat shock
protein 27 homozygous mutation: widening of the
continuum between MND/dHMN/CMT2. J Peripher Nerv
Syst 2015;20:419–421.
Echaniz-Laguna A, Geuens T, Petiot P, et al. Axonal
neuropathies due to mutations in small heat shock
proteins: clinical, genetic, and functional insights into
novel mutations. Hum Mutat 2017;38:556–568.
Zhao Z, Hashiguchi A, Hu J, et al. Alanyl-tRNA
synthetase mutation in a family with dominant distal
hereditary motor neuropathy. Neurology 2012;78:1644–
1649.
Richards S, Aziz N, Bale S, et al. Standards and guidelines
for the interpretation of sequence variants: a joint
consensus recommendation of the American College of
Medical Genetics and Genomics and the Association for
Molecular Pathology. Genet Med 2015;17:405–424.
Verschueren A. Motor neuropathies and lower motor
neuron syndromes. Rev Neurol (Paris) 2017;173:320–325.
Rossor AM, Kalmar B, Greensmith L, Reilly MM. The
distal hereditary motor neuropathies. J Neurol Neurosurg
Psychiatry 2012;83:6–14.
Cottenie E, Kochanski A, Jordanova A, et al. Truncating
and missense mutations in IGHMBP2 cause CharcotMarie Tooth disease type 2. Am J Hum Genet
2014;95:590–601.
Li X, Hu Z, Liu L, et al. A SIGMAR1 splice-site mutation
causes distal hereditary motor neuropathy. Neurology
2015;84:2430–2437.
Lupo V, Frasquet M, Sanchez-Monteagudo A, et al.
Characterising the phenotype and mode of inheritance of
patients with inherited peripheral neuropathies carrying
MME mutations. J Med Genet 2018;55:814–823.

ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

1737

MME Associated With AR-dHMN

21. Mohajeri MH, Wolfer DP. Neprilysin deficiencydependent impairment of cognitive functions in a mouse
model of amyloidosis. Neurochem Res 2009;34:717–726.
22. Miners S, van Helmond Z, Barker R, et al. Genetic
variation in MME in relation to neprilysin protein and
enzyme activity, Ab levels, and Alzheimer’s disease risk.
Int J Mol Epidemiol Genet 2012;3:30–38.
23. Pareyson D, Saveri P, Piscosquito G. Charcot-Marie-Tooth
disease and related hereditary neuropathies: from gene
function to associated phenotypes. Curr Mol Med
2014;14:1009–1033.
24. Frasquet M, Chumillas MJ, Vılchez JJ, et al. Phenotype
and natural history of inherited neuropathies caused by

1738

D. Hong et al.

HSJ1 c.352+1G>A mutation. J Neurol Neurosurg
Psychiatry 2016;87:1265–1268.

Supporting Information
Additional supporting information may be found online
in the Supporting Information section at the end of the
article.
Table S1. The clinical information of the additional 83
dHMN patients with unknown genetic cause.

ª 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.

